1
项与 Allo-RevCAR01-T-CD123(AvenCell Europe) 相关的临床试验Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123
The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R TM123 functions as a bridging module between Allo RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.
100 项与 Allo-RevCAR01-T-CD123(AvenCell Europe) 相关的临床结果
100 项与 Allo-RevCAR01-T-CD123(AvenCell Europe) 相关的转化医学
100 项与 Allo-RevCAR01-T-CD123(AvenCell Europe) 相关的专利(医药)
100 项与 Allo-RevCAR01-T-CD123(AvenCell Europe) 相关的药物交易